Clinical Trial Update: Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients [Phase 3]

View source ↗

Summary

Phase 3 trial completed evaluating propranolol for reducing epistaxis in hereditary hemorrhagic telangiectasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Propranolol (propranolol)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease | Phase 3 | Status: COMPLETED